TheEdgeResearch
Home / Stocks / MOLN

Molecular Partners AG (MOLN)

NASDAQ Healthcare Biotechnology
$2.52 ▼ -5.25%
Market Cap
$96.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.69
52-Wk Range
2.52-5.36
CEO
Patrick Amstutz
Country
CH
Currency
USD

Molecular Partners AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Schlieren, ZH, CH. The stock last traded at $2.52, down 5.25% on the session, giving a market capitalisation of $96.8M. On trailing twelve-month figures it carries a trailing P/E of -1.52, a net margin of 0.0%. Its beta of 0.69 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.52
Price / Sales
0.00
Price / Book
1.55
EV / EBITDA
-0.49
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.05
Current ratio
6.46
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
134
IPO date
2021-06-16
Headquarters
Schlieren, ZH, CH
About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.

Comparable companies

Molecular Partners AG is most often compared with the following Healthcare names:

ALECAPLTCRBPCRDFELTXMISTNKTXPEPGRANISAVA
More research on MOLN
MOLN technical analysis MOLN TheEdge Score Compare against peers
Open full interactive analysis & DCF →